Sanford C. Bernstein Strategic Decisions Conference

June 2, 2016

Forward Looking Statements and Adjusted Financial Information

This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-lookingstatements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similarexpressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speakonly as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information orfuture events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which aredifficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report onForm 10-K and our other reports filed with the Securities and Exchange Commission.

In addition to unaudited financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted financialmeasures that we believe provide investors and management with supplemental information relating to operating performance and trendsthat facilitate comparisons between periods and with respect to projected information. These adjusted measures are non-GAAP andshould be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typicallyexclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition ofunusual or non-recurring items. Other companies may define these measures in different ways. Further information relevant to theinterpretation of adjusted financial measures, and reconciliations of these adjusted financial measures to the most comparable GAAPmeasures, may be found on our website at www.Celgene.com in the “Investor Relations” section.

2

Our Mission & Vision

Celgene is building a preeminent global biopharmaceutical company focusedon the discovery, development and

commercialization of innovative therapiesfor unmet medical needs in cancer and

immune-inflammatory diseases

3

A Leading Global Biopharmaceutical Company

4

Unique R&DCapability

• Expertise in hematology, oncology, and immunology

• Diverse technology platforms• Rich pipeline

– 70 programs in preclinical development– 32 treatments in clinical trials– 24 pivotal / phase III programs underway

• Operations in >60 countries• Sales in >70 countries• Manufacturing facilities in U.S. and EU• Key research facilities in NJ, CA, MA,

WA and Spain• ~7,000 employees globally

Global, FullyIntegrated Portfolio of Leading Products

O U R F O C U S

Continuing to Execute on Four Strategic Imperatives

5

Operational excellenceOperational excellence

Capitalizing on strength in Hematology / OncologyCapitalizing on strength in Hematology / Oncology

Driving innovation and long-term growthDriving innovation and long-term growth

Building a leading global Inflammation & Immunology franchiseBuilding a leading global Inflammation & Immunology franchise

18%CAGR

2020 Targets On-Track

Net Product Sales($B)

Adjusted Diluted EPS($)

$9.2

2015 2017E 2020E

$6.75-$7.00

2015 2017E 2020E

>$2118%CAGR1 22%

CAGR23%CAGR1

>$13.00

6

Note: At currency exchange rates on April 28, 20161. ) CAGR calculated from 2015 to 2020.

$12.7-$13.0

$4.71

Celgene Hematology / Oncology Targets High Unmet NeedIndications with a Portfolio of Backbone Therapies

Source: Evaluate Pharma

7

Cel

gene

Hem

/Onc

Foc

us Multiple Myeloma

Myeloid

NHL

CLL

Therapeutic AreaTargeted Market Size ($B)2015E 2020E

$9 $16

$1.5 $2.4

$7 $13

$2 $7

Total $42 $89

Potential Therapies

CC-486

CC-486Solid Tumors $22 $51

Luspatercept

CC-90009

CC-122

CC-122

CC-122

Durvalumab

Durvalumab

VTX-2337Demcizumab

CART

CART

BCMA CART

CC-220

Durvalumab

Durvalumab

CAGR %

12

10

12

29

16

18

Marizomib

PNK-007IDH Platform

Products

• NDMM approvals in US, EU and Japan; early launch metrics strong• Backbone therapy in novel triplet combinations for MM• Ph III NHL program accelerating – first data expected in mid-16

• NDMM approvals in US, EU and Japan; early launch metrics strong• Backbone therapy in novel triplet combinations for MM• Ph III NHL program accelerating – first data expected in mid-16

• Strong US performance with leading market share position• Updated US label reflects overall survival benefit• Global expansion gaining momentum in the EU and Japan

• Strong US performance with leading market share position• Updated US label reflects overall survival benefit• Global expansion gaining momentum in the EU and Japan

• Expanding globally for PanC, mBC and NSCLC• Advancing I/O strategy in NSCLC, TNBC and PanC• Significant Ph III data flow expected beginning in 2017

• Expanding globally for PanC, mBC and NSCLC• Advancing I/O strategy in NSCLC, TNBC and PanC• Significant Ph III data flow expected beginning in 2017

Maximizing the Value of Our Commercial Portfolio

8

• NDMM approvals in US, EU and Japan; early launch metrics strong• Backbone therapy in novel triplet combinations for MM• Ph III NHL program accelerating – first data expected in mid-16

• NDMM approvals in US, EU and Japan; early launch metrics strong• Backbone therapy in novel triplet combinations for MM• Ph III NHL program accelerating – first data expected in mid-16

• Strong US performance with leading market share position• Updated US label reflects overall survival benefit• Global expansion gaining momentum in the EU and Japan

• Strong US performance with leading market share position• Updated US label reflects overall survival benefit• Global expansion gaining momentum in the EU and Japan

• Expanding globally for PanC, mBC and NSCLC• Advancing I/O strategy in NSCLC, TNBC and PanC• Significant Ph III data flow expected beginning in 2017

• Expanding globally for PanC, mBC and NSCLC• Advancing I/O strategy in NSCLC, TNBC and PanC• Significant Ph III data flow expected beginning in 2017

Maximizing the Value of Our Commercial Portfolio

9

Mid-2016

H1:17

H2:17

2018

Trial Expected Data

2018

REMARCDLBCL Maintenance

RELEVANCE®

1ST Line Follicular

AUGMENT®

Rel / Ref Follicular

MAGNIFY®

Rel / Ref Indolent

ROBUST®

ABC DLBCL

Significant Ph III Data Beginning in 2017 Expected to Accelerate Sales

Trial Expected Data

apact®Adjuvant Pancreatic

abound®

NSCLC

IMpower 130*Non-Squamous NSCLC

IMpower 131*Squamous NSCLC

IMpassion 130*TNBC

Momentum Accelerating in Ph III NHL Trials

Robust Life Cycle Programs Expected to Yield Ph III Data Beginning in Mid-16

*Roche Ph III trials in combination with atezolizumab

2017

2017

2018

2017

2017

CELMoDs®: CC-122CC-220

I/O Combos:DurvalumabBCMA CART

Anti-CD47NK Cells

Next-Gen HDACs:Ricolinostat

Next-Gen PI’s:Marizomib

Celgene Drugs in Development

Expanding Leadership in Multiple Myeloma

10

Building on the IMiD® Backbone Across All Lines of Multiple Myeloma

Standard Disease

Aggression

SCTInduction

SCTMaintenance NSCT

2L 3L+NDMM

High Risk / Aggressive

Disease

RVd+/- Mab

RVdRd + Mab

R + Ixa, R + Dara

PdPd + PI

Pd + MabRVdRd + Mab

R

P Triplets

Rd RVd Rd + Mab

R Triplets

P Triplets

Note: Reflects current approved indications and new combinations.

CC-486 Luspatercept IDH Platform

RS+ Low/Int Risk MDS

Beta-Thalessemia

IDH2 Mutant AML

Extending Our Leadership Position in Myeloid Diseases

Broad Phase III Program in MDS, AML and Beta-Thalessemia Underway

Luspatercept

RS+ Low/Int Risk MDS

Beta-Thalessemia

IDH Platform

IDH2 Mutant AML

CC-486

11

Durvalumab CC-90009 PNK-007Development Programs:

Targeting Sizable Markets with a Portfolio of Disruptive Oral Therapies

Source: Evaluate Pharma

12

Cel

gene

I&I F

ocus

Rheumatology

Dermatology

Gastroenterology / IBD

Neuro-Inflammation / MS

$27 $34

$11 $17

$9 $15

$20 $27

Total $67 $93

Targeted Indications

• PsA• Behçet’s• AS

• Psoriasis• Atopic Dermatitis

• CD• UC• EoE

• MS

CC-220

GED-0301

ozanimod RPC-4046

ozanimod

• SLE• Sjogrens

Therapeutic AreaProducts and

Potential Therapies

5

9

11

6

7

CC-292

ABX-1431

ozanimod

Targeted Market Size ($B)2015E 2020E CAGR %

OTEZLA® Market Dynamics Supporting Positive U.S. Launch Performance

13

• Repeat leader in new-to-brand share for both PsA and psoriasis; reaching 38% in PsA and 42% in psoriasis• Persistency similar to biologics and ahead of oral DMARDs

Source: Symphony Prescriber-level data through week ending 31 March 20161. S. Feldman et.al., Comparison of Persistence Between Adults With Psoriasis Initiating Apremilast or Biologics at The 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting

Psoriasis Market Share Surpassing Enbrel

0%5%

10%15%20%25%30%35%40%45%50%

ENBREL STELARA HUMIRA COSENTYX OTEZLA

OTEZLA®

20%

• At 6 months post-index, persistence to initiated drug was similar between the OTEZLA® and biologic cohorts (OTEZLA®: 67.2%, 95% CI: 63.6–70.5 vs biologics: 68.5%, 95% CI: 66.3–70.6)1

0%5%

10%15%20%25%30%35%40%45%50%

ENBREL HUMIRA STELARA CIMZIAREMICADE SIMPONI OTEZLA

PsA Market Share Continuing to Grow

OTEZLA 15%

Advancing a Robust Life Cycle Plan

14

Milestone Expected Timing

2018

New Indications in Development

Trial Expected Data

Enhancing the Opportunity in PsA and Psoriasis

20162016Bridging StudyOnce daily regimen

Q1:16Q1:16Japan NDA Filing

Q2:16Q2:16Phase IIAtopic Dermatitis

2016/172016/17Phase IIUlcerative Colitis

20162016Ankylosing SpondylitisLong-term follow-up

Phase IIIBehçets Disease 20172017

Q1:16Q1:16PSA-006 Phase IIIPsA biologic-naïve

• Potential first-in-class smad7 anti-sense treatment• Ph III program in CD underway; endoscopic data expected in 2017• Ph II trial in UC initiated

• Potential first-in-class smad7 anti-sense treatment• Ph III program in CD underway; endoscopic data expected in 2017• Ph II trial in UC initiated

• Potential best-in-class next-generation S1P receptor modulator• Ph III trial in UC underway; data expected in 2018• Ph II trial in CD initiated

• Potential best-in-class next-generation S1P receptor modulator• Ph III trial in UC underway; data expected in 2018• Ph II trial in CD initiated

• Novel PDE-4 inhibitor with unique clinical profile• Ph II trial in UC underway• Data expected in late 2016 / early 2017

• Novel PDE-4 inhibitor with unique clinical profile• Ph II trial in UC underway• Data expected in late 2016 / early 2017

Establishing Leadership in Inflammatory Bowel Diseases

15

GED-0301

Ozanimod

Advancing Differentiated Oral Therapies Through Mid-to-Late Stage Trials

Unique Distributed R&D Model Amplifies Internal Strengths

CELGENE PLATFORMS

FibrosisCancer

Stem Cells/Resistance

Immuno‐Oncology

EpigeneticsNext

GenerationBiologics

ProteinHomeostasis

Immunology

Novel IMiDs® /CRBN & OtherUbiquitin Ligase

Targets

New Targets, EpigeneticPriming &

Convergence w/ Metabolic Targets

GDF Family   PKC,BTKi, 

Novel Targets  JNK1, 

New Targets,Novel   

phenotypic  screens  

Payload Delivery,Next GenEnhanced Activities

Complementary      Approaches to  

I/O,Breaking Tumor   

ToleranceUnique    

Validation / Testing Capabilities fromTumor Tissue  

16

PH

Over 50 Potential New Product Approvals Possible Through 2025

CC-486 CC-90009

530

CC-90002

PH

CC-122

Luspatercept

I/O

I/O

EPI

AG-221 /AG-120

RicolinostatRicolinostat

BCMACARTMarizomib

Durvalumab CART

Gen Next-Gen Biologic

CC-220 CC-90005CC-90006

I&I CC-90001 I&II&I

Ozanimod

I&I

I&I I&I EPI

I&I

I&I

I&I

ABX-1431

SotaterceptSotatercept

CC-90010

CC-90003

TKI

EPI

EPI

EPIGen Next-Gen Biologic

Demcizumab

EPII/O

Motolimod

PH EPI

EPI

GED-0301

17

Next-GenBiologic

CC-90008

Hematology I & I Oncology

We Are Well Positioned to Grow Through the Next Decade

18

Total Sales Potential

2015 2030

Commercial Productsand

Mid-to-Late Stage Pipeline

50 Potential New Products

>100 Indications

Data from at Least 18 Phase III Trials Expected by 2018

19

2016 2017 2018

PSA-006Biologic-naïve PsA

ETNANeoadjuvant BC

CONTINUUM®

CLL maintenance

REMARCDLBCL maintenance

apact®Adjuvant PanC

AUGMENT®

RR fNHL

IMpower 130*I/O non-squamous NSCLC

SUNBEAMMS

IMpower 131*I/O squamous NSCLC

RADIANCEMS

RELEVANCE®

1st Line fNHL

OPTIMISMM®

2nd Line+ RRMM

IMpassion 130*I/O TNBC

abound®.sqmSquamous maintenance

RELIEFTM

Behçet’s

ozanimod

ozanimod TRUE NORTHUC

ozanimod

CD-003Crohn’s

GED-0301

CD-002Crohn’s

GED-0301

*Roche Ph III trial in combination with atezolizumab

Positioned For GrowthBeyond 2020

2020 and Beyond: Driving Sustainable, High Growth

On Track to Meet or Exceed 2020 Targets

Expanding, Extending and Establishing Leading Franchises

$4.71

23%CAGR

>$13.00

Adjusted EPS($)

2014 2017E 2020E 2015 2030

20

Total Sales Potential

2016 Anticipated Milestones

Regulatory Submissions/Decisions Submit REVLIMID® in U.S. and EU for maintenance post-ASCT Submit POMALYST® renal impairment data in US and EUX Submit ABRAXANE® for early-stage breast cancer in EU Submit OTEZLA® for PSOR in Japan CHMP opinion on REVLIMID® for MCL

Trial Enrollment Complete enrollment in AUGMENT® – REVLIMID® in RR FL Complete enrollment in apact® – ABRAXANE® in adjuvant PanC Complete enrollment in RELIEF® – OTEZLA® in Behçet’s disease Complete enrollment in ph II trial of CC-486 + pembrolizumab in NSCLC Initiate enrollment in ph I trial of BCMA CART in RRMM Initiate enrollment in FUSION™ program with durvalumab in NDMM,

RRMM, NHL, MDS/AML

Trial Initiations Initiate pivotal trial with CC-122 in NHL Initiate ph III trial with OTEZLA® in AD Initiate second ph III trial with GED-0301 Initiate ph III trial with RPC4046 in EoE

Financial Performance Total Net Product Sales between $10.75 to $11.0 billion1

Net REVLIMID® sales of $6.7 billion1

Adjusted operating margin of ~53.5% Adjusted EPS between $5.60 to $5.701

21

Clinical Data Ph III REMARC – REVLIMID® in DLCBL maintenance Ph III CONTINUUM® – REVLIMID® in CLL maintenanceX Ph III ETNA – ABRAXANE® in neoadjuvant BC Ph III POSTURE® – long-term radiographic data of OTEZLA® in AS Ph III PSA-006 – OTEZLA® in biologic-naïve PsA Ph II CC-122 in NHL Ph II motolimod (VTX-2337) in SCCHN and ovarian cancer Ph II portion of tnAcity® – ABRAXANE® in TNBC Ph II OTEZLA® in AD and UC Ph II CC-220 in SLE Ph II RPC4046 in EoE Pharmacokinetic comparability study – OTEZLA® once-daily formulation

R&ED File at least 8 IND’s Advance at least 2 compounds to mid-to-late stage development

1. Updated Q1:16

Sanford C. Bernstein Strategic Decisions Conference

June 2, 2016

Reconciliation Table

23

2015

2014

Net p

roduct

sales

9,161.

1$

7,563.

8$

Other

reven

ue94.

9

106

.6

To

tal rev

enue

9,256.

0

7,670.

4

Cost o

f good

s sold

(excl

uding

amort

ization

ofacq

uired

intangi

ble as

sets)

420.1

385.9

Resea

rch an

d deve

lopme

nt3,6

97.3

2,4

30.6

Se

lling, g

eneral

and a

dminis

trative

2,305.

4

2,027.

9

Amort

ization

of ac

quired

intang

ible as

sets

279.0

258.3

Acqui

sition

relate

d char

ges an

d rest

ructur

ing, ne

t299

.6

48.

7

To

tal cos

ts and

expens

es7,0

01.4

5,1

51.4

Opera

ting inc

ome

2,254.

6

2,519.

0

Intere

st and

invest

ment

incom

e, net

31.1

28.2

Intere

st (exp

ense)

(310.6

)

(176.1

)

Other

incom

e (exp

ense),

net

48.4

(43.7)

Incom

e befo

re inc

ome t

axes

2,023.

5

2,327.

4

Incom

e tax

provis

ion

421.5

327.5

Net in

come

1,602.

0$

1,999.

9$

Net in

come p

er com

mon s

hare:

Basic

2.02

$

2.49

$

Dilute

d1.9

4$

2.3

9$

Weigh

ted av

erage

shares

:Ba

sic792

.2

802

.7

Dil

uted

824.9

836.0

Balan

ce sh

eet it

ems:

Cash,

cash

equiva

lents &

mark

etable

secur

ities

Total

assets

Short

-term

borro

wings

and cu

rrent

portion

of lon

g-term

debt

Long-

term

debt

Total

stockh

olders

' equity

Twelv

e-Mont

h Peri

ods En

dedDe

cember

31,

Celge

ne C

orpora

tion a

nd Su

bsidia

ries

Cond

ensed

Con

solida

ted St

ateme

nts of

Inco

me(Un

audit

ed)(In

milli

ons, e

xcept

per sh

are da

ta)

Reconciliation Table

24

2015

2014

Net in

come -

GAAP

1,602.

0$

1,999.

9$

Befor

e tax

adjust

ments

: C

ost of

goods

sold (

exclud

ing am

ortiza

tion

of acq

uired

intangi

ble as

sets):

S

hare-b

ased c

ompen

sation

expen

se (1)

31.7

26.2

Rese

arch a

nd dev

elopm

ent:

S

hare-b

ased c

ompen

sation

expen

se(1)

250.7

196.5

U

pfront

collab

oration

expen

se(2)

1,402.

3

453.6

IP

R&D

impair

ment

(3)-

129.2

Selli

ng, ge

neral a

nd adm

inistra

tive:

S

hare-b

ased c

ompen

sation

expen

se(1)

294.2

224.9

S

ettlem

ent of

contin

gent o

bligatio

n(4)

-

25.

0

Amo

rtizatio

n of a

cquire

d intan

gible a

ssets

(5)279

.0

258

.3

Acqu

isition

relate

d (gai

ns) ch

arges

and re

struct

uring,

net:

C

hange

in fair

value

of co

ntingen

t cons

iderat

ion(6)

(7.9)

48.7

A

cquisit

ion co

sts(7)

297.6

-

Rest

ructur

ing ch

arges

(8)9.9

-

Net in

come t

ax adj

ustme

nts(9)

(277.1

)

(263.7

)

Net in

come

- Adju

sted

3,882.

4$

3,098.

6$

Net in

come p

er com

mon s

hare

- Adju

sted

Basic

4.90

$

3.86

$

Dilute

d4.7

1$

3.7

1$

Twelv

e-Mont

h Peri

ods En

dedDe

cember

31,

Celge

ne C

orpora

tion a

nd Su

bsidia

ries

Reco

ncilia

tion o

f GAA

P to A

djuste

d Net

Incom

e(In

milli

ons, e

xcept

per sh

are da

ta)

Reconciliation Table

25

Explanation of adjustments:(1) Exclude share-based compensation expense totaling $150.2 for the three-month period ended December 31, 2015 and $128.4 for the three-month

period ended December 31, 2014. Exclude share-based compensation expense totaling $576.6 for the twelve-month period ended December 31, 2015 and $447.6 for the twelve-month period ended December 31, 2014.

(2) Exclude upfront payment expense for research and development collaboration arrangements.(3) Exclude in-process research and development (IPR&D) impairment recorded as a result of changes in estimated probability-weighted cash flows

related to CC-292.(4) Exclude settlement of a contingent obligation to make matching contributions to a non-profit organization.(5) Exclude amortization of intangible assets acquired in the acquisitions of Pharmion Corp., Gloucester Pharmaceuticals, Inc. (Gloucester), Abraxis

BioScience Inc. (Abraxis), Celgene Avilomics Research, Inc. (Avila), and Quanticel Pharmaceuticals, Inc. (Quanticel).(6) Exclude changes in the fair value of contingent consideration related to the acquisitions of Gloucester, Abraxis, Avila, Nogra Pharma Limited and

Quanticel.(7) Exclude equity compensation and other fees and costs related to the acquisitions of Receptos, Inc. and Quanticel.(8) Exclude restructuring charges related to our relocation of certain operations into our two Summit, NJ locations as well as costs associated

with certain headcount reductions.(9) Net income tax adjustments reflect the estimated tax effect of the above adjustments and the impact of certain other non-operating tax adjustments,

including the effects of acquisition related matters, adjustments to the amount of unrecognized tax benefits, adjustments related to the gain on the sale of an equity investment and nonrecurring items connected with the launch of new products.

In addition to financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted financial measures are non-GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways.